Central Europe a hotspot for drug trials
trials it has been asked to work on in Central Europe, and believes
the trend is set to continue.
UK-based clinical research organisation Chiltern International says it has seen a marked increase in the number of trials it has been asked to work on in Central Europe, and believes the trend is set to continue.
Over the last decade the number of multi-centre clinical trials in the Central and Eastern Europe (CEE) region has been growing on average at an annual rate of 30%. According to Chiltern, this figure could rise even further.
"There are a number of advantages that the CEE region can offer for conducting clinical trials in terms of speed of recruitment, quality of data and value for money," explained Chiltern's clinical development manager for the CEE, Dr Boris Golubtsov.
"We, like others, have noticed a marked increase in demand for our expertise in central European areas like Poland, the Czech Republic and Ukraine and we believe there is a real chance that this demand will continue to rise,"he added.
Chiltern claims to be one of only a handful of companies to focus on providing Phase I to III clinical trial services in the CEE region.
